Literature DB >> 31522426

Clinical Flow-Cytometric Testing in Chronic Lymphocytic Leukemia.

Dalia A Salem1,2, Maryalice Stetler-Stevenson3.   

Abstract

Flow-cytometric demonstration of the typical chronic lymphocytic leukemia (CLL) immunophenotype is vital for diagnosis. CLL has a characteristic immunophenotype, expressing CD5, CD19, dim CD20, dim CD22, CD23, bright CD43, dim CD45, dim to negative CD79b, dim CD81, CD200, and dim monoclonal surface immunoglobulin. This characteristic immunophenotype allows a definitive diagnosis and the ruling out of another leukemia or lymphoma. Flow cytometry also provides important prognostic information and accurate assessment of response to therapy. Here we describe optimal specimen collection, red cell lysis, appropriate panel, cell staining, acquisition on a flow cytometer, and analysis for CLL specimens.

Entities:  

Keywords:  Chronic lymphocytic leukemia; Flow cytometry; Immunophenotype; Minimal residual disease

Mesh:

Substances:

Year:  2019        PMID: 31522426      PMCID: PMC8276061          DOI: 10.1007/978-1-4939-9650-6_17

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  18 in total

Review 1.  U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures.

Authors:  G T Stelzer; G Marti; A Hurley; P McCoy; E J Lovett; A Schwartz
Journal:  Cytometry       Date:  1997-10-15

2.  CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia.

Authors:  J Dürig; M Naschar; U Schmücker; K Renzing-Köhler; T Hölter; A Hüttmann; U Dührsen
Journal:  Leukemia       Date:  2002-01       Impact factor: 11.528

Review 3.  Diagnostic criteria for monoclonal B-cell lymphocytosis.

Authors:  Gerald E Marti; Andy C Rawstron; Paolo Ghia; Peter Hillmen; Richard S Houlston; Neil Kay; Thérèse A Schleinitz; Neil Caporaso
Journal:  Br J Haematol       Date:  2005-08       Impact factor: 6.998

4.  Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma.

Authors:  Daisy Alapat; Jean Coviello-Malle; Rebecca Owens; Pingping Qu; Bart Barlogie; John D Shaughnessy; Robert B Lorsbach
Journal:  Am J Clin Pathol       Date:  2012-01       Impact factor: 2.493

Review 5.  Implications of new prognostic markers in chronic lymphocytic leukemia.

Authors:  Nicholas Chiorazzi
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

6.  Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.

Authors:  Paul Moreton; Ben Kennedy; Guy Lucas; Michael Leach; Saad M B Rassam; Andrew Haynes; Jane Tighe; David Oscier; Christopher Fegan; Andy Rawstron; Peter Hillmen
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

7.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Authors:  R N Damle; T Wasil; F Fais; F Ghiotto; A Valetto; S L Allen; A Buchbinder; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; V P Vinciguerra; K R Rai; M Ferrarini; N Chiorazzi
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

8.  Phenotypic heterogeneity of B cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors:  Bal Kampalath; Maurice P Barcos; Carleton Stewart
Journal:  Am J Clin Pathol       Date:  2003-06       Impact factor: 2.493

9.  International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.

Authors:  A C Rawstron; N Villamor; M Ritgen; S Böttcher; P Ghia; J L Zehnder; G Lozanski; D Colomer; C Moreno; M Geuna; P A S Evans; Y Natkunam; S E Coutre; E D Avery; L Z Rassenti; T J Kipps; F Caligaris-Cappio; M Kneba; J C Byrd; M J Hallek; E Montserrat; P Hillmen
Journal:  Leukemia       Date:  2007-03-15       Impact factor: 11.528

10.  Validation of three viable-cell counting methods: Manual, semi-automated, and automated.

Authors:  Daniela Cadena-Herrera; Joshua E Esparza-De Lara; Nancy D Ramírez-Ibañez; Carlos A López-Morales; Néstor O Pérez; Luis F Flores-Ortiz; Emilio Medina-Rivero
Journal:  Biotechnol Rep (Amst)       Date:  2015-04-18
View more
  3 in total

1.  ALK-Positive Anaplastic Large-Cell Lymphoma in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review.

Authors:  Qinchuan Yu; Zhiqiang Zhao; He Wang; Lieyang Wang
Journal:  Onco Targets Ther       Date:  2022-10-19       Impact factor: 4.345

2.  The potential differential diagnosis value and clinical significance of CD35 expression in B-chronic lymphoproliferative disorders.

Authors:  Yu Shi; Lu Liu; Hui Yang; Xiao Chen; Yan Wang; Sishu Zhao; Huimin Jin; Yujie Wu
Journal:  Ann Transl Med       Date:  2021-07

3.  A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia.

Authors:  Yi Li; Xiwen Tong; Lifang Huang; Li Li; Chunyan Wang; Cheng He; Songya Liu; Zhiqiong Wang; Min Xiao; Xia Mao; Donghua Zhang
Journal:  Cancer Med       Date:  2021-06-01       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.